biotech · Melanoma · Previously untreated, unresectable, or metastatic melanoma · IOBTQ
IO Biotech
IO Biotech is a biotech organization headquartered in copenhagen, DK. It trades on NYSE under ticker IOBTQ. Primary therapeutic focus areas include Melanoma, Previously untreated, unresectable, or metastatic melanoma, ad
Ole Maaloesvej 3, Copenhagen, Denmark 2200, DK HQ
2015 Founded
50 Employees
Public company Type
IOBTQ · NYSE Ticker
Company details
- Status
- Public
- HQ
- Ole Maaloesvej 3, Copenhagen, Denmark 2200, DK
- Founded
- 2015
- Employees
- 50
- Programs
- 16
- Drugs
- 8
- Patents
- 21
IRX5183
Phase 1 · small molecule · Acute Myeloid Leukemia (AML)
IRX5183 for Acute Myeloid Leukemia (AML) is a Phase 1 program (small_molecule) at IO Biotech with 1 ClinicalTrials.gov record(s).
Internal code J15219
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- IO Biotech
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Acute Myeloid Leukemia (AML)
- Status
- terminated
- Trials
- 1